TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 ID - Bray2018 ER - TY - JOUR AU - Rahib, L. AU - Smith, B. D. AU - Aizenberg, R. AU - Rosenzweig, A. B. AU - Fleshman, J. M. AU - Matrisian, L. M. PY - 2014 DA - 2014// TI - Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-0155 DO - 10.1158/0008-5472.CAN-14-0155 ID - Rahib2014 ER - TY - JOUR AU - Kamisawa, T. AU - Wood, L. D. AU - Itoi, T. AU - Takaori, K. PY - 2016 DA - 2016// TI - Pancreatic cancer JO - Lancet. VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)00141-0 DO - 10.1016/S0140-6736(16)00141-0 ID - Kamisawa2016 ER - TY - JOUR AU - Luchini, C. AU - Capelli, P. AU - Scarpa, A. PY - 2016 DA - 2016// TI - Pancreatic ductal adenocarcinoma and its variants JO - Surg Pathol Clin VL - 9 UR - https://doi.org/10.1016/j.path.2016.05.003 DO - 10.1016/j.path.2016.05.003 ID - Luchini2016 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2020 DA - 2020// TI - Cancer statistics, 2020 JO - CA Cancer J Clin VL - 70 UR - https://doi.org/10.3322/caac.21590 DO - 10.3322/caac.21590 ID - Siegel2020 ER - TY - STD TI - I numeri del cancro in Italia 2019. https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operatori-web.pdf. Accessed 11 May 2020. UR - https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operatori-web.pdf ID - ref6 ER - TY - JOUR AU - Herbst, B. AU - Zheng, L. PY - 2019 DA - 2019// TI - Precision medicine in pancreatic cancer: treating every patient as an exception JO - Lancet Gastroenterol Hepatol VL - 4 UR - https://doi.org/10.1016/S2468-1253(19)30175-X DO - 10.1016/S2468-1253(19)30175-X ID - Herbst2019 ER - TY - JOUR AU - Waddell, N. AU - Pajic, M. AU - Patch, A. M. AU - Chang, D. K. AU - Kassahn, K. S. AU - Bailey, P. PY - 2015 DA - 2015// TI - Whole genomes redefine the mutational landscape of pancreatic cancer JO - Nature. VL - 518 UR - https://doi.org/10.1038/nature14169 DO - 10.1038/nature14169 ID - Waddell2015 ER - TY - JOUR AU - Bailey, P. AU - Chang, D. K. AU - Nones, K. AU - Johns, A. L. AU - Patch, A. M. AU - Gingras, M. C. PY - 2016 DA - 2016// TI - Genomic analyses identify molecular subtypes of pancreatic cancer JO - Nature. VL - 531 UR - https://doi.org/10.1038/nature16965 DO - 10.1038/nature16965 ID - Bailey2016 ER - TY - JOUR AU - Pylayeva-Gupta, Y. AU - Grabocka, E. AU - Bar-Sagi, D. PY - 2011 DA - 2011// TI - RAS oncogenes: weaving a tumorigenic web JO - Nat Rev Cancer VL - 11 UR - https://doi.org/10.1038/nrc3106 DO - 10.1038/nrc3106 ID - Pylayeva-Gupta2011 ER - TY - JOUR AU - Singhi, A. D. AU - George, B. AU - Greenbowe, J. R. AU - Chung, J. AU - Suh, J. AU - Maitra, A. PY - 2019 DA - 2019// TI - Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers JO - Gastroenterology VL - 156 UR - https://doi.org/10.1053/j.gastro.2019.02.037 DO - 10.1053/j.gastro.2019.02.037 ID - Singhi2019 ER - TY - STD TI - Luchini C, Veronese N, Nottegar A, Cappelletti V, Daidone MG, Smith L, Parris C, Brosens LAA, Caruso MG, Cheng L, Wolfgang CL, Wood LD, MilellaM, Salvia R, Scarpa A. Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine. Cancers (Basel). 2019;11:1152. ID - ref12 ER - TY - JOUR AU - Infante, J. R. AU - Somer, B. G. AU - Park, J. O. AU - Li, C. P. AU - Scheulen, M. E. AU - Kasubhai, S. M. PY - 2014 DA - 2014// TI - A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2014.04.024 DO - 10.1016/j.ejca.2014.04.024 ID - Infante2014 ER - TY - JOUR AU - Cutsem, E. AU - Hidalgo, M. AU - Canon, J. L. AU - Macarulla, T. AU - Bazin, I. AU - Poddubskaya, E. PY - 2018 DA - 2018// TI - Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer JO - Int J Cancer VL - 143 UR - https://doi.org/10.1002/ijc.31603 DO - 10.1002/ijc.31603 ID - Cutsem2018 ER - TY - JOUR AU - Laethem, J. L. AU - Riess, H. AU - Jassem, J. AU - Haas, M. AU - Martens, U. M. AU - Weekes, C. PY - 2017 DA - 2017// TI - Phase I/II study of refametinib (BAY 86–9766) in combination with gemcitabine in advanced pancreatic cancer JO - Target Oncol VL - 12 UR - https://doi.org/10.1007/s11523-016-0469-y DO - 10.1007/s11523-016-0469-y ID - Laethem2017 ER - TY - JOUR AU - Bodoky, G. AU - Timcheva, C. AU - Spigel, D. R. AU - Stella, P. J. AU - Ciuleanu, T. E. AU - Pover, G. PY - 2012 DA - 2012// TI - A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy JO - Investig New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9687-4 DO - 10.1007/s10637-011-9687-4 ID - Bodoky2012 ER - TY - JOUR AU - Dueland, S. AU - Valle, J. W. AU - Bell, K. AU - Faluyi, O. AU - Staiger, H. AU - Gjertsen, T. J. PY - 2017 DA - 2017// TI - TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx369.053 DO - 10.1093/annonc/mdx369.053 ID - Dueland2017 ER - TY - JOUR AU - Eriksen, J. A. AU - Gladhaug, I. P. AU - Rosseland, A. AU - Risberg Handeland, K. AU - Buanes, T. PY - 2017 DA - 2017// TI - An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx376.018 DO - 10.1093/annonc/mdx376.018 ID - Eriksen2017 ER - TY - JOUR AU - Richards, D. AU - Muscarella, P. AU - Bekaii-Saab, T. AU - Wilfong, L. AU - Rosemurgy, A. AU - Ross, S. PY - 2012 DA - 2012// TI - A phase 2 adjuvant trial of GI-4000 plus gemcitabine vs. gemcitabine alone in ras+ patients with resected pancreas cancer: R1 subgroup analysis JO - Ann Oncol VL - 23 UR - https://doi.org/10.1016/S0923-7534(19)66467-7 DO - 10.1016/S0923-7534(19)66467-7 ID - Richards2012 ER - TY - JOUR AU - Weden, S. AU - Klemp, M. AU - Gladhaug, I. P. AU - Moller, M. AU - Eriksen, J. A. AU - Gaudernack, G. PY - 2011 DA - 2011// TI - Long term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras JO - Int J Cancer VL - 128 UR - https://doi.org/10.1002/ijc.25449 DO - 10.1002/ijc.25449 ID - Weden2011 ER - TY - JOUR AU - Singh, R. R. AU - Goldberg, J. AU - Varghese, A. M. AU - Yu, K. H. AU - Park, W. AU - O'Reilly, E. M. PY - 2019 DA - 2019// TI - Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: a scoping review JO - Cancer Treat Rev VL - 75 UR - https://doi.org/10.1016/j.ctrv.2019.03.003 DO - 10.1016/j.ctrv.2019.03.003 ID - Singh2019 ER - TY - JOUR AU - Laheru, D. AU - Shah, P. AU - Rajeshkumar, N. V. AU - McAllister, F. AU - Taylor, G. AU - Goldsweig, H. PY - 2012 DA - 2012// TI - Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer JO - Investig New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-012-9818-6 DO - 10.1007/s10637-012-9818-6 ID - Laheru2012 ER - TY - JOUR AU - Cutsem, E. AU - Velde, H. AU - Karasek, P. AU - Oettle, H. AU - Vervenne, W. L. AU - Szawlowski, A. PY - 2004 DA - 2004// TI - Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.10.112 DO - 10.1200/JCO.2004.10.112 ID - Cutsem2004 ER - TY - JOUR AU - Yan, Z. AU - Ohuchida, K. AU - Fei, S. AU - Zheng, B. AU - Guan, W. AU - Feng, H. PY - 2019 DA - 2019// TI - Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-019-1226-8 DO - 10.1186/s13046-019-1226-8 ID - Yan2019 ER - TY - JOUR AU - Sun, Y. AU - Peng, W. AU - He, W. AU - Luo, M. AU - Chang, G. AU - Shen, J. PY - 2018 DA - 2018// TI - Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer JO - J Exp Clin Cancer Res VL - 37 UR - https://doi.org/10.1186/s13046-018-0818-z DO - 10.1186/s13046-018-0818-z ID - Sun2018 ER - TY - STD TI - Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8:a031435. ID - ref26 ER - TY - JOUR AU - Kim, S. T. AU - Lim, D. H. AU - Jang, K. T. AU - Lim, T. AU - Lee, J. AU - Choi, Y. L. PY - 2011 DA - 2011// TI - Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-11-0269 DO - 10.1158/1535-7163.MCT-11-0269 ID - Kim2011 ER - TY - JOUR AU - Windon, A. L. AU - Loaiza-Bonilla, A. AU - Jensen, C. E. AU - Randall, M. AU - Morrissette, J. J. D. AU - Shroff, S. G. PY - 2018 DA - 2018// TI - A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma JO - J Gastrointest Oncol VL - 9 UR - https://doi.org/10.21037/jgo.2017.10.14 DO - 10.21037/jgo.2017.10.14 ID - Windon2018 ER - TY - JOUR AU - Mottini, C. AU - Tomihara, H. AU - Carrella, D. AU - Lamolinara, A. AU - Iezzi, M. AU - Huang, J. K. PY - 2019 DA - 2019// TI - Predictive signatures inform the effective repurposing of Decitabine to treat KRAS-dependent pancreatic ductal adenocarcinoma JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-19-0187 DO - 10.1158/0008-5472.CAN-19-0187 ID - Mottini2019 ER - TY - JOUR AU - Furukawa, T. PY - 2015 DA - 2015// TI - Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer JO - Front Oncol VL - 5 UR - https://doi.org/10.3389/fonc.2015.00023 DO - 10.3389/fonc.2015.00023 ID - Furukawa2015 ER - TY - STD TI - Thatcher JD. The Ras-MAPK signal transduction pathway. Sci Signal. 2010;3:tr1. ID - ref31 ER - TY - JOUR AU - Gibbs, J. B. AU - Sigal, I. S. AU - Poe, M. AU - Scolnick, E. M. PY - 1984 DA - 1984// TI - Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules JO - Proc Natl Acad Sci U S A VL - 81 UR - https://doi.org/10.1073/pnas.81.18.5704 DO - 10.1073/pnas.81.18.5704 ID - Gibbs1984 ER - TY - JOUR AU - Davies, H. AU - Bignell, G. R. AU - Cox, C. AU - Stephens, P. AU - Edkins, S. AU - Clegg, S. PY - 2002 DA - 2002// TI - Mutations of the BRAF gene in human cancer JO - Nature. VL - 417 UR - https://doi.org/10.1038/nature00766 DO - 10.1038/nature00766 ID - Davies2002 ER - TY - JOUR AU - Milella, M. AU - Falcone, I. AU - Conciatori, F. AU - Matteoni, S. AU - Sacconi, A. AU - Luca, T. PY - 2017 DA - 2017// TI - PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep43013 DO - 10.1038/srep43013 ID - Milella2017 ER - TY - JOUR AU - Ciuffreda, L. AU - Curatolo, A. AU - Falcone, I. AU - Conciatori, F. AU - Bazzichetto, C. AU - Cognetti, F. PY - 2017 DA - 2017// TI - Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx335 DO - 10.1093/annonc/mdx335 ID - Ciuffreda2017 ER - TY - JOUR AU - Chung, V. AU - McDonough, S. AU - Philip, P. A. AU - Cardin, D. AU - Wang-Gillam, A. AU - Hui, L. PY - 2017 DA - 2017// TI - Effect of Selumetinib and MK-2206 vs Oxaliplatin and fluorouracil in patients with metastatic pancreatic Cancer after prior therapy: SWOG S1115 study randomized clinical trial JO - JAMA Oncol VL - 3 UR - https://doi.org/10.1001/jamaoncol.2016.5383 DO - 10.1001/jamaoncol.2016.5383 ID - Chung2017 ER - TY - JOUR AU - Johnson, G. L. AU - Lapadat, R. PY - 2002 DA - 2002// TI - Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases JO - Science. VL - 298 UR - https://doi.org/10.1126/science.1072682 DO - 10.1126/science.1072682 ID - Johnson2002 ER - TY - JOUR AU - Brunet, A. AU - Roux, D. AU - Lenormand, P. AU - Dowd, S. AU - Keyse, S. AU - Pouyssegur, J. PY - 1999 DA - 1999// TI - Nuclear translocation of p42/p44 mitogen activated protein kinase is required for growth factor-induced gene expression and cell cycle entry JO - EMBO J VL - 18 UR - https://doi.org/10.1093/emboj/18.3.664 DO - 10.1093/emboj/18.3.664 ID - Brunet1999 ER - TY - JOUR AU - Pishvaian, M. J. AU - Bender, R. J. AU - Halverson, D. AU - Rahib, L. AU - Hendifar, A. E. AU - Mikhail, S. PY - 2018 DA - 2018// TI - Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0531 DO - 10.1158/1078-0432.CCR-18-0531 ID - Pishvaian2018 ER - TY - STD TI - Wrzeszczynski KO, Rahman S, Frank MO, Arora K, Shah M, Geiger H, Felice V, Manaa D, Dikoglu E, Khaira D, Chimpiri AR, Michelini VV, JobanputraV, Darnell RB, Powers S, Choi M. Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma. Cold Spring Harb Mol Case Stud. 2019;5:a004424. ID - ref40 ER - TY - JOUR AU - Curatolo, A. AU - Conciatori, F. AU - Cesta Incani, U. AU - Bazzichetto, C. AU - Falcone, I. AU - Corbo, V. PY - 2018 DA - 2018// TI - Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models JO - J Exp Clin Cancer Res VL - 37 UR - https://doi.org/10.1186/s13046-018-0820-5 DO - 10.1186/s13046-018-0820-5 ID - Curatolo2018 ER - TY - JOUR AU - Wilentz, R. E. AU - Goggins, M. AU - Redston, M. AU - Marcus, V. A. AU - Adsay, N. V. AU - Sohn, T. A. PY - 2000 DA - 2000// TI - Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity JO - Am J Pathol VL - 156 UR - https://doi.org/10.1016/S0002-9440(10)65035-3 DO - 10.1016/S0002-9440(10)65035-3 ID - Wilentz2000 ER - TY - JOUR AU - Lupinacci, R. M. AU - Bachet, J. B. AU - André, T. AU - Duval, A. AU - Svrcek, M. PY - 2019 DA - 2019// TI - Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine JO - Surg Oncol VL - 28 UR - https://doi.org/10.1016/j.suronc.2018.11.019 DO - 10.1016/j.suronc.2018.11.019 ID - Lupinacci2019 ER - TY - BOOK AU - Luchini, C. AU - Brosens, L. A. AU - Wood, L. D. AU - Chatterjee, D. AU - Shin, J. AU - Sciammarella, C. PY - 2020 DA - 2020// TI - Comprehensive characterization of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications, gut UR - https://doi.org/10.1136/gutjnl-2020-320726 DO - 10.1136/gutjnl-2020-320726 ID - Luchini2020 ER - TY - JOUR AU - Luchini, C. AU - Bibeau, F. AU - Ligtenberg, M. J. L. AU - Singh, N. AU - Nottegar, A. AU - Bosse, T. PY - 2019 DA - 2019// TI - ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz116 DO - 10.1093/annonc/mdz116 ID - Luchini2019 ER - TY - STD TI - Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, Sadowska J, Berger MF, Delair DF, Shia J, Stadler Z, Klimstra DS, Ladanyi M, Zehir A, Hechtman JF. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol. 2017;2017:PO.17.00084. ID - ref46 ER - TY - JOUR AU - Salipante, S. J. AU - Scroggins, S. M. AU - Hampel, H. L. AU - Turner, E. H. AU - Pritchard, C. C. PY - 2014 DA - 2014// TI - Microsatellite instability detection by next generation sequencing JO - Clin Chem VL - 60 UR - https://doi.org/10.1373/clinchem.2014.223677 DO - 10.1373/clinchem.2014.223677 ID - Salipante2014 ER - TY - JOUR AU - Humphris, J. L. AU - Patch, A. M. AU - Nones, K. AU - Bailey, P. J. AU - Johns, A. L. AU - McKay, S. PY - 2017 DA - 2017// TI - Hypermutation in pancreatic Cancer JO - Gastroenterology VL - 152 UR - https://doi.org/10.1053/j.gastro.2016.09.060 DO - 10.1053/j.gastro.2016.09.060 ID - Humphris2017 ER - TY - JOUR AU - Salem, M. E. AU - Puccini, A. AU - Grothey, A. AU - Raghavan, D. AU - Goldberg, R. M. AU - Xiu, J. PY - 2018 DA - 2018// TI - Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers JO - Mol Cancer Res VL - 16 UR - https://doi.org/10.1158/1541-7786.MCR-17-0735 DO - 10.1158/1541-7786.MCR-17-0735 ID - Salem2018 ER - TY - JOUR AU - Hu, Z. I. AU - Shia, J. AU - Stadler, Z. K. AU - Varghese, A. M. AU - Capanu, M. AU - Salo-Mullen, E. PY - 2018 DA - 2018// TI - Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-3099 DO - 10.1158/1078-0432.CCR-17-3099 ID - Hu2018 ER - TY - JOUR AU - Lupinacci, R. M. AU - Goloudina, A. AU - Buhard, O. AU - Bachet, J. B. AU - Maréchal, R. AU - Demetter, P. PY - 2018 DA - 2018// TI - Prevalence of microsatellite instability in Intraductal papillary mucinous neoplasms of the pancreas JO - Gastroenterology. VL - 154 UR - https://doi.org/10.1053/j.gastro.2017.11.009 DO - 10.1053/j.gastro.2017.11.009 ID - Lupinacci2018 ER - TY - JOUR AU - Lothe, R. A. AU - Peltomaki, P. AU - Meling, G. I. AU - Aaltonen, L. A. AU - Nyström-Lahti, M. AU - Pylkkänen, L. PY - 1993 DA - 1993// TI - Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history JO - Cancer Res VL - 53 ID - Lothe1993 ER - TY - JOUR AU - Llosa, N. J. AU - Cruise, M. AU - Tam, A. AU - Wicks, E. C. AU - Hechenbleikner, E. M. AU - Taube, J. M. PY - 2015 DA - 2015// TI - The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints JO - Cancer Discov. VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-14-0863 DO - 10.1158/2159-8290.CD-14-0863 ID - Llosa2015 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Brahmer, J. R. AU - Tykodi, S. S. AU - Chow, L. Q. AU - Hwu, W. J. AU - Topalian, S. L. AU - Hwu, P. PY - 2012 DA - 2012// TI - Safety and activity of anti-PD-L1 antibody in patients with advanced cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200694 DO - 10.1056/NEJMoa1200694 ID - Brahmer2012 ER - TY - JOUR AU - Royal, R. E. AU - Levy, C. AU - Turner, K. AU - Mathur, A. AU - Hughes, M. AU - Kammula, U. S. PY - 2010 DA - 2010// TI - Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma JO - J Immunother VL - 33 UR - https://doi.org/10.1097/CJI.0b013e3181eec14c DO - 10.1097/CJI.0b013e3181eec14c ID - Royal2010 ER - TY - JOUR AU - Le, D. T. AU - Durham, J. N. AU - Smith, K. N. AU - Wang, H. AU - Bartlett, B. R. AU - Aulakh, L. K. PY - 2017 DA - 2017// TI - Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade JO - Science. VL - 357 UR - https://doi.org/10.1126/science.aan6733 DO - 10.1126/science.aan6733 ID - Le2017 ER - TY - JOUR AU - Marabelle, A. AU - Le, D. T. AU - Ascierto, P. A. AU - Giacomo, A. M. AU - Jesus-Acosta, A. AU - Delord, J. P. PY - 2020 DA - 2020// TI - Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.19.02105 DO - 10.1200/JCO.19.02105 ID - Marabelle2020 ER - TY - JOUR AU - Singhi, A. D. AU - Ali, S. M. AU - Lacy, J. AU - Hendifar, A. AU - Nguyen, K. AU - Koo, J. PY - 2017 DA - 2017// TI - Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma JO - J Natl Compr Cancer Netw VL - 15 UR - https://doi.org/10.6004/jnccn.2017.0058 DO - 10.6004/jnccn.2017.0058 ID - Singhi2017 ER - TY - STD TI - Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. J Clin Oncol. 2018;36(4_suppl):521. ID - ref60 ER - TY - JOUR AU - Chmielecki, J. AU - Hutchinson, K. E. AU - Frampton, G. M. AU - Chalmers, Z. R. AU - Johnson, A. AU - Shi, C. PY - 2014 DA - 2014// TI - Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes JO - Cancer Discov. VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-14-0617 DO - 10.1158/2159-8290.CD-14-0617 ID - Chmielecki2014 ER - TY - JOUR AU - Aguirre, A. J. AU - Nowak, J. A. AU - Camarda, N. D. AU - Moffitt, R. A. AU - Ghazani, A. A. AU - Hazar-Rethinam, M. PY - 2018 DA - 2018// TI - Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine JO - Cancer Discov. VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0275 DO - 10.1158/2159-8290.CD-18-0275 ID - Aguirre2018 ER - TY - JOUR AU - Jonna, S. AU - Feldman, R. A. AU - Swensen, J. AU - Gatalica, Z. AU - Korn, W. M. AU - Borghaei, H. PY - 2019 DA - 2019// TI - Detection of NRG1 gene fusions in solid tumors JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-19-0160 DO - 10.1158/1078-0432.CCR-19-0160 ID - Jonna2019 ER - TY - JOUR AU - Yarden, Y. AU - Pines, G. PY - 2012 DA - 2012// TI - The ERBB network: at last, cancer therapy meets systems biology JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3309 DO - 10.1038/nrc3309 ID - Yarden2012 ER - TY - JOUR AU - Jones, M. R. AU - Williamson, L. M. AU - Topham, J. T. AU - Lee, M. K. AU - Goytain, A. AU - Ho, J. PY - 2019 DA - 2019// TI - NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma JO - Clin Cancer Res VL - 25 ID - Jones2019 ER - TY - JOUR AU - Heining, C. AU - Horak, P. AU - Uhrig, S. AU - Codo, P. L. AU - Klink, B. AU - Hutter, B. PY - 2018 DA - 2018// TI - NRG1 fusions in KRAS wild-type pancreatic Cancer JO - Cancer Discov. VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0036 DO - 10.1158/2159-8290.CD-18-0036 ID - Heining2018 ER - TY - JOUR AU - Drilon, A. AU - Somwar, R. AU - Mangatt, B. P. AU - Edgren, H. AU - Desmeules, P. AU - Ruusulehto, A. PY - 2018 DA - 2018// TI - Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-1004 DO - 10.1158/2159-8290.CD-17-1004 ID - Drilon2018 ER - TY - JOUR AU - Luchini, C. AU - Capelli, P. AU - Fassan, M. AU - Simbolo, M. AU - Mafficini, A. AU - Pedica, F. PY - 2014 DA - 2014// TI - Next-generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2012.47.5855 DO - 10.1200/JCO.2012.47.5855 ID - Luchini2014 ER - TY - JOUR AU - Golan, T. AU - Hammel, P. AU - Reni, M. AU - Cutsem, E. AU - Macarulla, T. AU - Hall, M. J. PY - 2019 DA - 2019// TI - Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic Cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1903387 DO - 10.1056/NEJMoa1903387 ID - Golan2019 ER - TY - JOUR AU - Tang, M. AU - Chen, J. AU - Goldstein, D. AU - Links, M. AU - Lord, S. AU - Marschner, I. PY - 2019 DA - 2019// TI - Evaluation of phase II trial Design in Advanced Pancreatic Cancer JO - Pancreas. VL - 48 UR - https://doi.org/10.1097/MPA.0000000000001429 DO - 10.1097/MPA.0000000000001429 ID - Tang2019 ER - TY - JOUR AU - Martino, M. T. AU - Meschini, S. AU - Scotlandi, K. AU - Riganti, C. AU - Smaele, E. AU - Zazzeroni, F. PY - 2020 DA - 2020// TI - From single gene analysis to single cell profiling: a new era for precision medicine JO - J Exp Clin Cancer Res VL - 39 UR - https://doi.org/10.1186/s13046-020-01549-3 DO - 10.1186/s13046-020-01549-3 ID - Martino2020 ER - TY - JOUR AU - Pishvaian, M. J. AU - Blais, E. M. AU - Brody, J. R. AU - Lyons, E. AU - DeArbeloa, P. AU - Hendifar, A. PY - 2020 DA - 2020// TI - Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial JO - Lancet Oncol VL - 21 UR - https://doi.org/10.1016/S1470-2045(20)30074-7 DO - 10.1016/S1470-2045(20)30074-7 ID - Pishvaian2020 ER -